Autosomal Dominant Polycystic Disease is Associated with Depressed Levels of Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand

Abstract

Background: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by multiple, large renal cysts and impaired kidney function. Although the reason for the development of kidney cysts is unknown, ADPKD is associated with cell cycle arrest and abundant apoptosis of renal tubular epithelial cells. Aims: We asked whether serum-soluble TNF-related apoptosis-inducing ligand (sTRAIL) might underlie ADPKD. Study Design: Case-control study. Methods: Serum sTRAIL levels were measured in 44 patients with ADPKD and 18 healthy volunteers. The human soluble TRAIL/Apo2L ELISA kit was used for the in vitro quantitative determination of sTRAIL in serum samples. Results: Mean serum sTRAIL levels were lower in patients with ADPKD as compared to the control group (446.9±103.1 and 875.9±349.6 pg/mL, p<0.001). Serum sTRAIL levels did not differ among stages of renal failure in patients with ADPKD. There was no correlation between serum sTRAIL levels and estimated glomerular filtration rate in patients with ADPKD (p>0.05). Conclusion: Our results show that ADPKD patients have depressed sTRAIL levels, indicating apoptosis unrelated to the stage of chronic renal failure.

Keywords

• Serum-soluble TNF-related apoptosis-inducing ligand, chronic kidney disease, autosomal dominant polycystic kidney disease

Kaynakça

1. 1. Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med 1993;329:332–42. [CrossRef]
2. 2. Gattone VH 2nd, Calvet JP, Cowley BD Jr, Evan AP, Shaver TS, Helmstader K, et al. Autosomal recessive polycystic kidney disease in a murine model. A gross and microscopic description. Lab Invest 1988;59:231–8.
3. 3. Zhou XJ, Kukes G. Pathogenesis of autosomal dominant polycystic kidney disease: role of apoptosis. Diagn Mol Pathol 1998;7:65-8. [CrossRef]
4. 4. Lanoix J, D’Agati V, Szabolcs M, Trudel M. Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD). Oncogene 1996;13:1153-60.
5. 5. Woo D. Apoptosis and loss of renal tissue in polycystic kidney diseases. N Engl J Med 1995;333:18-25. [CrossRef]
6. 6. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673– 82. [CrossRef]
7. 7. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687–90. [CrossRef]
8. 8. Corallini F, Rimondi E, Secchiero P. TRAIL and osteoprotegerin: a role in endothelial physiopathology? Front Biosci 2008;13:135-47. [CrossRef]

9. 9. Pan G, O’Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111–3. [CrossRef]
10. 10. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997;16:5386–97. [CrossRef]
11. 11. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-8. [CrossRef]
12. 12. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-21. [CrossRef]
13. 13. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NFkappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997;7:813–20. [CrossRef]
14. 14. Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003;63:912–6.
15. 15. Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H. Nature’s TRAIL-on a path to cancer immunotherapy. Immunity 2003;18:1–6. [CrossRef]
16. 16. Liabeuf S, Barreto DV, Barreto FC, Chasseraud M, Brazier M, Choukroun G, et al. The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients. Nephrol Dial Transplant 2010;25:2596-602. [CrossRef]
17. 17. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al A New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med 2009;150:604-12. [CrossRef]
18. 18. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. National Kidney Foundation. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.
19. 19. Murcia NS, Sweeney WE Jr, Avner ED. New insights into the molecular pathophysiology of polycystic kidney disease. Kidney Int 1999;55:1187-97. [CrossRef]
20. 20. Trudel M, Barisoni L, Lanoix J, D’Agati V. Polycystic kidney disease in SBM transgenic mice: role of c-myc in disease induction and progression. Am J Pathol 1998;152:219-29.
21. 21. Winyard PJ, Nauta J, Lirenman DS, Hardman P, Sams VR, Risdon RA, et al. Deregulation of cell survival in cystic and dysplastic renal development. Kidney Int 1996;49:135-46. [CrossRef]
22. 22. Ecder T, Melnikov VY, Stanley M, Korular D, Lucia MS, Schrier RW, et al. Caspases, Bcl-2 proteins and apoptosis in autosomaldominant polycystic kidney disease. Kidney Int 2002;61:1220- 30. [CrossRef]
23. 23. Agostini M, Tucci P, Melino G. Cell death pathology: perspective for human diseases. Biochem Biophys Res Commun 2011;414:451-5. [CrossRef]